Got RA? Don't Delay!

JULY 01, 2002

When it comes to beginning treatment for rheumatoid arthritis, minutes and seconds may not count, but weeks and months surely do.

In a 3-year study at the University Hospital of Vienna and at Lainz Hospital in Austria, researchers found that there is a definite "window of opportunity" for successful treatment.

The study compared patients with very early disease who had waited an average of 3 months before being started on drugs to a group who had waited 20 months to start therapy.

After just 3 months of treatment, patients with early therapy were doing better than those who had waited longer. At the end of the study, 70% of patients in the early-treatment group showed a 20% improvement in disease symptoms. Meanwhile, only 40% of those in the later-treatment group improved.

The researchers concluded that introducing disease-modifying drugs very early "seems highly beneficial in [rheumatoid arthritis] compared with even relatively short delay."



SHARE THIS SHARE THIS
0
 

In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine

Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.


 

 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.